Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis A Clinical Trial.  American Journal of Respiratory and Critical Care Medicine.  205:529-539. 2022
2022 Bone mineral density screening by DXA for people with cystic fibrosis: A registry analysis of patient and program factors influencing rates of screening.  Journal of Cystic Fibrosis.  2022
2022 Exploring provider attitudes and perspectives related to men's health in cystic fibrosis.  Journal of Cystic Fibrosis.  2022
2022 Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies–A qualitative study.  Journal of Cystic Fibrosis.  2022
2021 Most short children with cystic fibrosis do not catch up by adulthood.  Nutrients.  13. 2021
2021 Men's health in the modern era of cystic fibrosis.  Journal of Cystic Fibrosis.  20:e121-e123. 2021
2021 Barriers to retinopathy screening in youth and young adults with type 1 diabetes.  Pediatric Diabetes.  22:469-473. 2021
2021 PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.  Journal of Cystic Fibrosis.  20:205-212. 2021
2021 Real-World Screening for Retinopathy in YouthWith Type 1 Diabetes Using a Nonmydriatic Fundus Camera.  Diabetes Spectrum.  34:27-33. 2021
2019 Growth failure and treatment in cystic fibrosis.  Journal of Cystic Fibrosis.  18:S82-S87. 2019
2017 Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient rat.  PLoS ONE.  12. 2017
2017 Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life.  JAMA Pediatrics.  171:546-554. 2017
2017 Growth in prepubertal children with cystic fibrosis treated with ivacaftor.  Pediatrics.  139. 2017
2013 Cystic fibrosis-related bone disease: Insights into a growing problem 2013
2013 Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease.  PLoS ONE.  8. 2013
2012 A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis.  Pediatric Pulmonology.  47:252-263. 2012
2009 Endocrine parameters of cystic fibrosis: Back to basics.  Journal of Cellular Biochemistry.  108:353-361. 2009
2009 Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation.  Pediatric Research.  65:311-316. 2009
2008 CFTR mutations impart elevated immune reactivity in a murine model of cystic fibrosis related diabetes.  Cytokine.  44:154-159. 2008
2008 Growth hormone therapy improves growth in children with cystic fibrosis related liver disease.  Journal of Pediatric Endocrinology and Metabolism.  21:793-797. 2008
2007 A long-term evaluation of the juvenile diabetic.  Journal of Pediatrics.  150:105. 2007
2006 Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after β-cell injury.  Diabetes.  55:1939-1945. 2006
2005 Diabetes acceleration or prevention by a coxsackievirus B4 infection: Critical requirements for both interleukin-4 and gamma interferon.  Journal of Virology.  79:1045-1052. 2005
2004 Predictors of control of diabetes: Monitoring may be the key.  Journal of Pediatrics.  144:660-661. 2004
1995 Blepharophimosis syndrome is linked to chromosome 3q.  Human Molecular Genetics.  4:443-448. 1995

Principal Investigator On

Investigator On

Education And Training

  • University of Florida - Gainesville, Internship
  • University of Florida - Gainesville, Residency
  • University of Florida - Gainesville, Postdoctoral Fellowship
  • Doctor of Medicine, University of Florida 1999
  • Bachelor of Science or Mathematics in Zoology / Animal Biology, University of Florida 1992

    • Full Name

  • Michael Stalvey